A recent study published in the Clinical Journal of Medicine, sheds light on the remarkable potential of NORDBIOTIC probiotic strains in providing relief to adult patients suffering from Irritable Bowel Syndrome (IBS). The study, titled “The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or Bacillus coagulans in Adult Patients with Irritable Bowel Syndrome—A Randomized Double-Blind Placebo-Controlled Three-Arm Interventional Trial,” conducted a comprehensive assessment of the effects of Bifidobacterium lactis NORDBIOTICTM BI040 and Bacillus coagulans NORDBIOTICTM BC300 in a prospective three-arm interventional randomized double-blind placebo-controlled clinical trial.
IBS is a common gastrointestinal disorder characterized by abdominal pain and discomfort along with changes in bowel frequency and stool consistency. The study, involving 123 IBS patients diagnosed according to the Rome IV criteria, focused on evaluating the efficacy and safety of single-strain probiotic formulations as an alternative therapeutic approach for IBS management.
The key findings of the study are as follows:
Positive Symptom Improvement: Both Bifidobacterium lactis and Bacillus coagulans probiotic strains demonstrated significant improvements in IBS symptom severity. After 12 weeks of intervention, IBS-SSS scores showed a notable decrease in all study groups, indicating a reduction in symptom severity.
Species-Specific Effects: Bifidobacterium lactis primarily reduced the frequency and intensity of pain, while Bacillus coagulans increased bowel satisfaction among IBS patients.
Stool Consistency Improvement: Both probiotic strains enhanced stool consistency, with a notable increase in the percentage of patients reporting normal stool consistency.
Safe and Well-Tolerated: The study established that both Bifidobacterium lactis and Bacillus coagulans probiotics were safe and well-tolerated by IBS patients, with no significant differences in the occurrence of adverse events between the study groups.
Long-Term Benefits: After finishing the intervention, the Bifidobacterium lactis group displayed a sustained reduction in pain frequency and intensity, while the Bacillus coagulans group exhibited enhanced bowel satisfaction.
These results highlight the potential of NORDBIOTIC probiotic strains in providing relief to IBS patients. The study emphasizes the importance of selecting the appropriate probiotic strains tailored to individual patient needs. NORDBIOTIC probiotics offer a promising avenue for IBS management, contributing to improved quality of life for individuals dealing with this challenging condition.
For more information about the study, please refer to the article titled “The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or Bacillus coagulans in Adult Patients with Irritable Bowel Syndrome,” published in the Clinical Journal of Medicine 2023, 12, 4838 (https://doi.org/10.3390/jcm12144838). The study is registered under ClinicalTrials.gov with the identifier NCT05064930.
About Nordic BioticTM – Research and Development Company Focused on Microbiome Advancements
Nordic BioticTM is an R&D company with a distinct focus on microbiome research. Our primary objective is to provide probiotic actives that cater to the global market’s needs. With a robust research pipeline, we are dedicated to addressing critical health areas such as osteoporosis, Hashimoto’s, hypercholesterolemia, gut health and immunity. Our company’s core mission revolves around enhancing human health through the potential of beneficial microbiome bacteria. This efficacy is firmly grounded in scientific validation: “Proven by Science. NaturallyTM.”
Reference
Skrzydło-Radomańska, B., et al. (2023). The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or Bacillus coagulans in Adult Patients with Irritable Bowel Syndrome—A Randomized Double-Blind Placebo-Controlled Three-Arm Interventional Trial. Journal of Clinical Medicine, 12(14), 4838.
